Cosmo Pharmaceuticals N.V.
Dublin, Ireland – 6 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2022 results on Thursday, 28 July 2022 at 07:00 am CEST. Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast which will follow at 2:00 pm CEST with Alessandro Della Chà, CEO, and Niall Donnelly, CFO, to discuss the financial and operating results and next milestones of the company.
Live conference call and video webcast presentation:
||Thursday, 28 July 2022
||2:00 pm CEST
Participant webcast link: Chrome (recommended) or Firefox
Please note that there is a function to type in your questions via webcast.
Participants wishing to ask verbal questions via phone, may call the following numbers below. To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.
|Switzerland / Europe
||+41 (0) 58 310 50 00
||+44 (0) 207 107 06 13
||+1 (1) 631 570 56 13
The presentation and press release as well as the Half-Year Report 2022 will be available for download as of 07:00 am CEST on 28 July 2022 at www.cosmopharma.com.
The webcast, along with the presentation will be available online shortly after the event and accessible for three months.
|Upcoming Calendar of Events
|Half-Year 2022 Report
||July 28, 2022
|Commerzbank and ODDO BHF Conference
||September 6-8, 2022
|Investora Conference, Zurich
||September 21-22, 2022
|Credit Suisse Equity Forum Switzerland
||November 15-17, 2022
|Jefferies 2022 London Healthcare Conference
||November 15-17, 2022
Cosmo is a pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally by selected partners including Lialda®, Uceris®/Cortiment® and Winlevi®. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ which uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo® to Red Hill Biopharma Ltd. for the US and has licensed Relafalk® to Dr. Falk Gmbh for the EU and other countries. The company also has a rich development pipeline. For additional information on Cosmo and its products please visit the Company’s website: www.cosmopharma.com
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.